Pfizer

Pfizer(PFE)

NEW YORK, NY
Pharmaceutical2 H-1B visas (FY2023)

Focus: Solid Oral Dosage Forms

Pfizer is a life sciences company focused on Solid Oral Dosage Forms.

OncologyImmunologyRare DiseasesVaccinesInternal Medicine
Funding Stage
PUBLIC
Employees
88,000
Open Jobs
614

Products & Portfolio (11)

39 discontinued products not shown

ABRILADA
adalimumab-afzb
Peak
mAbINJECTION · INJECTABLE
TNF-alpha and block its interaction with the p55 and p75 cell surface TNF receptors. Adalimumab products also lyse surface TNF expressing cells in vitro in the presence of complement. Adalimumab products do not bind or inactivate lymphotoxin (TNF-beta). TNF is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Elevated concentrations of TNF are found in the synovial fluid of patients with RA, JIA, PsA, and AS and play an important role in both the pathologic inflammation and the joint destruction that are hallmarks of these diseases. Increased concentrations of TNF are also found in psoriasis plaques. In Ps, treatment with ABRILADA may reduce the epidermal thickness and infiltration of inflammatory cells. The relationship between these pharmacodynamic activities and the mechanism(s) by which adalimumab products exert their clinical effects is unknown. Adalimumab products also modulate biological responses that are induced or regulated by TNF, including changes in the concentrations of adhesion molecules responsible for leukocyte migration (ELAM-1, VCAM-1, and ICAM-1 with an IC 50 of 1–2 × 10M).
moderately to severely active Crohn's disease in adultsoldermoderately to severely active ulcerative colitis in adult patients+10 more
2019
30
ACETYLCYSTEINE
acetylcysteine
Post-LOE
INHALATION, ORAL · SOLUTION
Reduction Activity
asthma
1994
30
ACETYLCYSTEINE
acetylcysteine
Post-LOE
INHALATION, ORAL · SOLUTION
Reduction Activity
asthma
1994
30
ADCETRIS
brentuximab vedotin
Peak
ADCINJECTION · INJECTABLE
CD30 is a member of the tumor necrosis factor receptor family and is expressed on the surface of sALCL cells and on Hodgkin Reed-Sternberg (HRS) cells in cHL. CD30 is variably expressed in other T-cell lymphomas. Expression of CD30 on healthy tissue and cells is limited. In vitro data suggest that signaling through CD30-CD30L binding may affect cell survival and proliferation. Brentuximab vedotin is an antibody-drug conjugate (ADC). The antibody is a chimeric IgG1 directed against CD30. The small molecule, MMAE, is a microtubule-disrupting agent. MMAE is covalently attached to the antibody via a linker. Nonclinical data suggest that the anticancer activity of ADCETRIS is due to the binding of the ADC to CD30-expressing cells, followed by internalization of the ADC‑CD30 complex, and the release of MMAE via proteolytic cleavage. Binding of MMAE to tubulin disrupts the microtubule network within the cell, subsequently inducing cell cycle arrest and apoptotic death of the cells. Additionally, in vitro data provide evidence for antibody-dependent cellular phagocytosis (ADCP).
IV cHLcombination with doxorubicinvinblastine+22 more
2011
30
ADCETRIS
brentuximab vedotin
Peak
ADCINJECTION · INJECTABLE
CD30-directed Antibody Interactions
IV cHLcombination with doxorubicinvinblastine+22 more
2011
30
ADRENALIN
epinephrine
Peak
INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS · SOLUTION
Adrenergic alpha-Agonists
2012
0
ADRENALIN
epinephrine
Peak
INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS · SOLUTION
Adrenergic alpha-Agonists
2013
0
ADRENALIN
epinephrine in sodium chloride
Growth
INTRAVENOUS · SOLUTION
Adrenergic alpha-Agonists
2023
0
ALDACTONE
spironolactone
LOE Approaching
ORAL · TABLET
Aldosterone Antagonists
NYHA Class III–IV heart failurereduced ejection fraction to increase survivalmanage edema+16 more
1960
30
ALISKIREN HEMIFUMARATE
aliskiren
Post-LOE
ORAL · TABLET
perfusion. Renin cleaves angiotensinogen to form the inactive decapeptide angiotensin I (Ang I). Ang I is converted to the active octapeptide angiotensin II (Ang II) by ACE and non-ACE pathways. Ang II is a powerful vasoconstrictor and leads to the release of catecholamines from the adrenal medulla and prejunctional nerve endings. It also promotes aldosterone secretion and sodium reabsorption. Together, these effects increase blood pressure. Ang II also inhibits renin release, thus providing a negative feedback to the system. This cycle, from renin through angiotensin to aldosterone and its associated negative feedback loop, is known as the renin-angiotensin-aldosterone system (RAAS). Aliskiren is a direct renin inhibitor, decreasing plasma renin activity (PRA) and inhibiting the conversion of angiotensinogen to Ang I. Whether aliskiren affects other RAAS components, e.g., ACE or non-ACE pathways, is not known. All agents that inhibit the RAAS, including renin inhibitors, suppress the negative feedback loop, leading to a compensatory rise in plasma renin concentration. When this rise occurs during treatment with ACEIs and ARBs, the result is increased levels of PRA. During treatment with aliskiren, however, the effect of increased renin levels is blocked so that PRA, Ang I and Ang II are all reduced, whether aliskiren is used as monotherapy or in combination with other antihypertensive agents.
hypertension in adultsgreaterto lower blood pressure+3 more
2019
30
ALLOPURINOL
allopurinol
Post-LOE
ORAL · TABLET
Xanthine Oxidase Inhibitors
leukemialymphoma
2003
30

Pipeline & Clinical Trials

N/A
Clinical Trials (5)
NCT02092467Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis
Phase 4
NCT06112665ToFAcitinib in Early Active Axial SpondyloarThritis:
Phase 4
NCT02187055An Efficacy And Safety Study Evaluating Tofacitinib With And Without Methotrexate Compared To Adalimumab With Methotrexate
Phase 4

+2 more

Arm 1: E-portal message with IVR call
Influenza
N/A
Clinical Trials (1)
NCT02266277System Alignment for VaccinE Delivery (SAVED): Improving Rates of Influenza and Pneumococcal Vaccination Through Patient Outreach, Improved Medical Record Accuracy and Targeted Physician Alerts
N/A
Real-World Outcome Research Study on Quality of Life, Work Productivity and Health Care Resource Uti
Metastatic Breast Cancer
N/A
Clinical Trials (1)
NCT02315365Real-World Outcome Research Study on Quality of Life, Work Productivity and Health Care Resource Utilization in Metastatic Breast Cancer
N/A
Clinical Trials (5)
NCT04184336Enhanced Population-based Core Surveillance of Meningococcal Invasive Infections at Participating Centers Across Canada
N/A
NCT05754710Korea Xeljanz Post-marketing Surveillance for Juvenile Idiopathic Arthritis
N/A
NCT04889495A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer
N/A

+2 more

No intervention
Alzheimer Disease
N/A
Clinical Trials (5)
NCT03823794Trends in the Epidemiology and Treatment of Atopic Dermatitis in the United Kingdom (UK)
N/A
NCT01856569Assial - Anti Tnf Treatment in Ankylosing Spondylitis: an Observational Cohort Study in Italy
N/A
NCT05198245Study of Pregnancy Outcomes in Women Exposed to Rimegepant During Pregnancy
N/A

+2 more

Clinical Trials (5)
NCT00110487Study Evaluating ERB-041 in Endometriosis in Reproductive-Age Women
Phase 2
NCT00434187Study to Evaluate Multiple Doses of ERB-041 in Healthy, Female Japanese Subjects
Phase 1
NCT00245947Study Evaluating ERB-041 in Active Crohn's Disease
Phase 1

+2 more

N/A
Clinical Trials (5)
NCT01176916Aromasin® Interventional Study Of Early Invasive Breast Cancer Patients In China
Phase 4
NCT01237327Multicenter Follow Up Study Of Subjects Who Participated In An Original Protocol Of Exemestane Vs. Megestrol Acetate In Postmenopausal Women With Metastatic Breast Cancer
Phase 3
NCT00036270Randomized Phase III Study Of Exemestane (Aromasin) For 5 Years Versus Tamoxifen for 2.5 to 3 Years Followed By Exemestane
Phase 3

+2 more

Treadmill testing
Heart Rate
N/A
Clinical Trials (1)
NCT00143988Heart Rate and Blood Pressure Response During Exercise and Sexual Activity in Normotensive and Hypertensive Volunteers
N/A
TNF blockers monotherapy
Rheumatoid Arthritis
N/A
Clinical Trials (1)
NCT02927535Evaluation of TNFα Blockers Monotherapy in Early Rheumatoid Arthritis in France
N/A
Clinical Trials (5)
NCT00793871Safety And Efficacy Study Of Sunitinib Malate In Chinese Patients With Imatinib Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor
Phase 4
NCT00706706Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma
Phase 4
NCT03013946Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy
Phase 3

+2 more

Clinical Trials (1)
NCT01620996A Novel Approach to Cardiovascular Health by Optimizing Risk Management (ANCHOR)
N/A
NewSpringForMe digital solution
Hematologic Diseases
N/A
Clinical Trials (5)
NCT03642132Avelumab and Talazoparib in Untreated Advanced Ovarian Cancer (JAVELIN OVARIAN PARP 100)
Phase 3
NCT02603432A Study Of Avelumab In Patients With Locally Advanced Or Metastatic Urothelial Cancer (JAVELIN Bladder 100)
Phase 3
NCT05059522Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
Phase 3

+2 more

Enhanced Clinical Intervention
Bipolar Disorder
N/A
N/A
Clinical Trials (5)
NCT02200406Desvenlafaxine in Opioid-Dependent Patients
Phase 4
NCT00952653Study Evaluating the Effect of Desvenlafaxine on the Pharmacokinetics of Midazolam
Phase 4
NCT01492621Effect of Antidepressants on White Matter Structure
Phase 4

+2 more

Tofacitinib
Blau Syndrome
N/A
Clinical Trials (1)
NCT06688838Effective Treatment of Jak1/3 Inhibitor in Blau Syndrome
N/A
Smoking cessation
Smoking Cessation
N/A
Clinical Trials (5)
NCT00596882Message Priming and Enrollment in, and Response to, a Smoking Cessation Program: A Pilot Study
Phase 4
NCT00889720A Pilot Study Of Smoking Cessation Treatment Including Varenicline In Patients Scheduled For Planned Surgery
Phase 4
NCT00818207Impact Of Smoking Cessation Treatment Reimbursement On The Quit Rates In Smokers Motivated To Quit
Phase 4

+2 more

Pregabalin
Neuralgia
N/A
Clinical Trials (5)
NCT01603394Pilot Study Of Pregabalin And Prediction Of Treatment Response In Patients With Postherpetic Neuralgia
Phase 4
NCT01226667Fixed Versus Flexible Dosing of Pregabalin in Patients With Fibromyalgia
Phase 4
NCT00407511Pregabalin Treatment Of Peripheral Neuropathic Pain Associated With Diabetic Peripheral NeP (DPN), Postherpetic Neuralgia (PHN), HIV-related NeP (HIV), and Chemotherapy Induced NeP
Phase 4

+2 more

No Patient Counseling
Medication Non-Adherence
N/A
Clinical Trials (1)
NCT01078285Effectiveness Of A Program That Includes Counseling And Patient Support On Adherence To Treatment With Lipitor
N/A
Rheumatoid Arthritis Satisfaction Outcome Research
Rheumatoid Arthritis
N/A
Clinical Trials (1)
NCT03703817Rheumatoid Arthritis Satisfaction Outcome Research
N/A
consultation 10 days later
Depression
N/A
Clinical Trials (1)
NCT01707576Screening of Adolescent Mental Suffering
N/A
Clinical Trials (1)
NCT04555603Axitinib Therapy Management Study
N/A
Hanyang University Medical Center Arthritis Network
Arthritis, Rheumatoid
N/A
Clinical Trials (1)
NCT00418405Hanyang University Medical Center Arthritis Network
N/A
Palbociclib + endocrine therapy
Breast Neoplasms
N/A
Clinical Trials (1)
NCT04767594First-line Palbociclib and Endocrine Therapy for Patients With HR+/HER2- Advanced Breast Cancer in the Real-world Setting.
N/A
Somatropin and pegvisomant
Metabolism
N/A
Clinical Trials (1)
NCT00476879Growth Hormone During Fasting.Signaltransduktion in Muscle and Adipose Tissue and Changes in Intrahepatic Lipid Content
N/A
Biochemical and Radiological Indicators of Cardiovascular Morbidity in Children With Premature Pubar
Evidence of Cardiovascular Morbidity
N/A
Clinical Trials (1)
NCT00581490Biochemical and Radiological Indicators of Cardiovascular Morbidity in Children With Premature Pubarche
N/A
Clinical Trials (5)
NCT01721408A Study To Determine The Efficacy And Safety Of Tigecycline Compared With Imipenem/Cliastatin to Treat Complicated Intra-Abdominal Infection
Phase 4
NCT01560143Pharmacokinetics Of Tigecycline In Morbidly Obese Subjects
Phase 4
NCT00230971Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection (cIAI)
Phase 4

+2 more

Triadic parent-infant Relationship Therapy
Preterm Birth
N/A
Clinical Trials (1)
NCT02394444Impact of an Intervention Program on Parenting Stress After Preterm Birth
N/A
HIV Cohort Study At Johns Hopkins University, University of North Carolina at Chapel Hill and Vander
HIV
N/A
Clinical Trials (1)
NCT01339416HIV Cohort Study At Johns Hopkins University, University of North Carolina at Chapel Hill and Vanderbilt University
N/A
Persistent SARS-CoV-2 Infection in Children With Cancer and Impaired Immune Responsiveness
Children With Cancer
N/A
Clinical Trials (1)
NCT05172063Persistent SARS-CoV-2 Infection in Children With Cancer and Impaired Immune Responsiveness
N/A
Focus Group
Breast Cancer
N/A
Clinical Trials (1)
NCT04504201Patient-centered Communication About Healthy Weight in Early Breast Cancer
N/A
Atorvastatin
Hyperlipidemia
N/A
Clinical Trials (1)
NCT00172419The Effects of Atorvastatin on Vulnerable Plaques in Untreated Dyslipidemic Patients.
N/A
Clinical Trials (1)
NCT00195338Study Evaluating Enbrel In Adults With Active Rheumatoid Arthritis In Luxemburg
N/A
N/A
Clinical Trials (5)
NCT00948155Measuring Smoking Behaviors While Using Varenicline
Phase 4
NCT01836276Understanding Disparities in Quitting in African American and White Smokers
Phase 4
NCT00749658Human Laboratory Study of Varenicline and Bupropion for Nicotine Dependence
Phase 2/3

+2 more

Retrospective Identification of Scintigraphic Cardiac Amyloidosis (RISCA)
Cardiac Amyloidosis
N/A
Clinical Trials (1)
NCT06921408Retrospective Identification of Scintigraphic Cardiac Amyloidosis (RISCA)
N/A
Retrospective Epidemiology Study Of ALK Rearrangement In Non-Small Cell Lung Cancer Patients In The
Non-small Cell Lung Cancer
N/A
Clinical Trials (1)
NCT02304406Retrospective Epidemiology Study Of ALK Rearrangement In Non-Small Cell Lung Cancer Patients In The Middle East & North Africa
N/A
N/A
Clinical Trials (1)
NCT06613984Korean Post Marketing Surveillance for Comirnaty Injection (Bretovameran)
N/A
Primary Exposure Status of Pfizer-BioNTech COVID-19 Vaccine
COVID-19
N/A
Clinical Trials (1)
NCT04848584Pfizer-BioNTech COVID-19 Vaccine Effectiveness Study - Kaiser Permanente Southern California
N/A
Clinical Trials (1)
NCT01121549A Non-Interventional Study With Aromasin® As Adjuvant Treatment Of Invasive Early Breast Cancer
N/A
Open Label Treatment Access: Maraviroc
Human Immunodeficiency Virus (HIV)
N/A
Clinical Trials (1)
NCT00992654A Treatment Access Program To Provide Maraviroc To Eligible Adult Patients Completing A4001050 Study Until Commercial Availability Of Maraviroc (Celsentri) In India
N/A
maraviroc
HIV
N/A
Clinical Trials (1)
NCT01329783EuroSIDA As An External Comparator To MOTIVATE Trials
N/A
Study Evaluating Enbrel (Etanercept) in Patients With Ankylosing Spondylitis
Ankylosing Spondylitis
N/A
Clinical Trials (1)
NCT00227227Study Evaluating Enbrel (Etanercept) in Patients With Ankylosing Spondylitis
N/A
Palbociclib + an aromatase inhibitor
Metastatic Breast Cancer
N/A
Clinical Trials (1)
NCT04176354Real-world Treatment Patterns and Effectiveness of Palbociclib and AI Therapy
N/A
smoking questionnaire
Plaque Psoriasis
N/A
Clinical Trials (1)
NCT02192164Non-interventional Study of the Effect of Smoking Status of the Patient on the Success of Etanercept Therapy in Psoriasis
N/A
Refacto AF
Hemophilia A
N/A
Clinical Trials (5)
NCT00037544Study Evaluating ReFacto AF in Severe Hemophilia A
Phase 3
NCT00243659Study Evaluating B-Domain Deleted Recombinant Factor VIII (BDDrFVIII, ReFacto AF) in Patients With Hemophilia A Undergoing Elective Major Surgery
Phase 3
NCT00038935Study Evaluating BDDRFVIII and ReFacto AF in Hemophilia A
Phase 3

+2 more

Clinical Trials (5)
NCT00836745Non-Interventional Study Of Indian Patients With Advanced Renal Cell Cancer Receiving Therapy With Sutent
N/A
NCT01947894A Prospective Non-Interventional Study Protocol With Primary Data Collection - Assessment Of The Long Term Treatment Outcomes Of Genotropin Treatment In Growth Hormone Deficiency (GHD) Patients
N/A
NCT00858143Non Interventional Study For Patients Treated With Somavert®
N/A

+2 more

Assessment of the Effectiveness and Safety Outcome in Patients With Atrial Fibrillation Treated by A
Atrial Fibrillation
N/A
Clinical Trials (1)
NCT05116267Assessment of the Effectiveness and Safety Outcome in Patients With Atrial Fibrillation Treated by Apixaban in Belgium
N/A
N/A
Clinical Trials (1)
NCT01660334Voriconazole (Vfend) Special Investigation (Regulatory Post Marketing Commitment Plan)
N/A
pegaptanib sodium
Macular Degeneration
N/A
Clinical Trials (5)
NCT00324116Evaluation Of Safety And Efficacy Of 0.3 Mg/Eye Macugen In Patients With Small Age-Related Macular Degeneration Lesions
Phase 4
NCT01175070Intravitreal Macugen for Ischaemic Diabetic Macular Oedema
Phase 4
NCT01486771Macugen for Proliferative Diabetic Retinopathy Study With Extended Dosing (M-PDRS ED)
Phase 4

+2 more

Open Jobs (614)

Senior Oncology Account Specialist Hematology Detroit, MI

Remote
Manufacturing
23h ago
$109K - $251K/yr

VP, Head of Oncology Biometrics

United States - Washington – Bothell
Data Science & AI
23h ago
$274K - $457K/yr

Neuroscience Health and Science Professional - Springfield, MA

United States - Massachusetts - Springfield
Manufacturing
23h ago
$72K - $187K/yr

Global Commercial Lead, Fetrastobart Vedotin

United States - New York - New York City
Commercial
23h ago
$215K - $358K/yr

高级医学信息沟通专员

China - Shandong - Qingdao
23h ago

[MA] Lung Cancer MAS team, ONC Field MAS [Manager/Staff]

Japan - Tokyo
23h ago

[JDSU] 医薬品安全性統括部 ケースマネジメントチーム(一般社員) (Staff, Case Management, Japan Drug Safety Unit)

Japan - Tokyo
Pharmacovigilance
23h ago

Manager, Digital and Technology, Controllers Delivery

United States - New York - New York City
23h ago
$99K - $165K/yr

Senior Associate Scientist

United States - Massachusetts - Andover
Research & Development
23h ago
$69K - $114K/yr

Healthcare Access Manager

Saudi Arabia - Jeddah
Commercial
23h ago

Product Owner

Belgium - Puurs
23h ago

Senior Health Representative (Oncology - North region)

Viet Nam - Hanoi
23h ago

Material Handler - 8 Hour Day Shift

United States - Kansas - McPherson
Manufacturing
23h ago

Senior Associate Scientist- Formulations

United States - Massachusetts - Andover
Research & Development
23h ago
$69K - $114K/yr

Senior Process Technician - Rotating 2nd Shift

United States - Massachusetts - Andover
Manufacturing
23h ago
$27 - $45/hr

Field Medical Manager, Oncology

Malaysia - Kuala Lumpur
Business Development
23h ago

National Account Manager Jr - Mendoza

Argentina - Buenos Aires
Commercial
23h ago

Trainee Supervisor

India - Vizag
Manufacturing
23h ago

Team Leader

India - Vizag
Manufacturing
23h ago

辉瑞制药-高级医学信息沟通专员-偏头痛-天津

China - Tianjin - Tianjin
IT
23h ago

高级医学信息沟通专员

China - Shandong - Qingdao
23h ago

医学信息沟通专员

China - Guangdong - Guangzhou
23h ago

高级客户解决方案专员

China - Beijing - Beijing
23h ago

Customs and Compliance Operations Manager

Viet Nam - Ho Chi Minh
Legal & IP
23h ago

Senior Manager, HTA, Value and Evidence (HV&E), Medical Dermatology

United States - New York - New York City
23h ago
$139K - $232K/yr
View all 614 open positions →
Interview Prep Quick Facts
Portfolio: 1472 approved products, 204 clinical trials
Top TAs: Oncology, Neurology, Infectious Diseases
H-1B (2023): 2 approvals
Publications: 25 in PubMed
SEC Filings: 2 available
Open Roles: 614 active jobs
Portfolio Health
Pre-Launch231 (16%)
Growth10 (1%)
Peak58 (4%)
LOE Approaching510 (35%)
Post-LOE663 (45%)
1472 total products
Therapeutic Area Focus
Oncology
81 marketed1265 pipeline
Neurology
96 marketed393 pipeline
Infectious Diseases
50 marketed337 pipeline
Immunology
46 marketed320 pipeline
Cardiovascular
73 marketed229 pipeline
Metabolic Diseases
10 marketed228 pipeline
Respiratory
38 marketed99 pipeline
Nephrology
13 marketed104 pipeline
Marketed
Pipeline

Financials (FY2025)

Revenue
$59.6B41%
R&D Spend
$10.7B(18%)7%
Net Income
$2.1B
Cash
$1.0B

Hiring Trend

Actively Hiring
614
Open Roles
+667
Added
-53
Filled/Removed

Based on last 3 crawl cycles

Visa Sponsorship

Sponsors Work Visas
H-1B Petitions (FY2023)
2
Approved
0
Denied
100%
Rate

Source: USCIS H-1B Employer Data Hub